Seqens is a France‑headquartered chemical and pharmaceutical manufacturer operating as a global contract development and manufacturing organization (CDMO). The company develops and produces active pharmaceutical ingredients (APIs), advanced intermediates, and high‑purity specialty chemicals, supporting customers from route design and process development through clinical and commercial supply. Its network of GMP and non‑GMP facilities and R&D centers spans Europe, North America, and Asia, with quality systems aligned to major regulatory requirements.
Alongside small‑molecule drug substances, Seqens supplies specialty ingredients for life‑science and industrial markets, including personal care and health & nutrition. Core services cover custom synthesis, process optimization and scale‑up, multi‑step organic synthesis, purification, and comprehensive analytical and regulatory support. The company emphasizes reliable, traceable, and compliant manufacturing with a focus on supply chain security and responsiveness to customer needs.
To provide comprehensive coverage, we aggregate data and news under the name Seqens, encompassing the following company names, divisions, and related entities:
SEQENS SAS, SEQENS, and CELLforCURE by SEQENS.
This list encompasses current and former names, alternate names, and key divisions associated with Seqens, ensuring you can easily find all relevant information under a single, unified profile.
